基于分子分型的交界性卵巢肿瘤生育力保护策略：从基础到临床
Fertility-Sparing Strategies for Borderline Ovarian Tumors Based on Molecular Classification: From Bench to Bedside
DOI: 10.12677/acm.2025.1551490, PDF,   
作者: 黄 颖, 令狐华*：重庆医科大学附属第一医院妇产科，母胎医学重庆市重点实验室/生殖与发育教育部国际合作联合实验室/母胎医学创新引智基地，重庆
关键词: 交界性卵巢肿瘤；生育力保护；分子分型；Borderline Ovarian Tumors； Fertility Preservation； Molecular Classification
摘要: 交界性卵巢肿瘤(borderline ovarian tumors, BOTs)是一类具有独特生物学特征的卵巢肿瘤，好发于育龄期女性。虽然保留生育功能手术(fertility-sparing surgery, FSS)已成为这类患者的首选治疗方式，但由于BOTs仍具有恶性转化和转移的潜在风险，临床决策面临重大挑战。目前尚缺乏可靠的生物标志物来预测BOTs向低级别浆液性癌(low-grade serous carcinoma, LGSC)的进展风险，这使得临床医生在平衡肿瘤安全性和生育力保护时面临困境。BOTs显著的生物学异质性进一步增加了手术方式选择、辅助治疗决策和随访策略制定的复杂性。本文系统综述了当前BOTs分子分型研究的最新进展，旨在为临床实践提供更精准的决策依据，并为未来研究方向提供新的思路。
Abstract: Borderline ovarian tumors (BOTs) constitute a distinct category of ovarian neoplasms with unique biological characteristics, primarily affecting women of reproductive age. While fertility-sparing surgery (FSS) has become the preferred therapeutic strategy for these patients, clinical management remains challenging due to the potential risks of malignant transformation and metastasis. Currently, reliable biomarkers for predicting the progression risk of BOTs to low-grade serous carcinoma (LGSC) remain elusive, posing a therapeutic dilemma in balancing oncological safety and fertility preservation. The significant biological heterogeneity of BOTs further complicates surgical approach selection, adjuvant therapy decisions, and follow-up strategy formulation. This review systematically summarizes recent advances in molecular classification of BOTs, aiming to provide more precise evidence for clinical decision-making and offer new perspectives for future research directions.
文章引用：黄颖, 令狐华. 基于分子分型的交界性卵巢肿瘤生育力保护策略：从基础到临床[J]. 临床医学进展, 2025, 15(5): 1268-1274. https://doi.org/10.12677/acm.2025.1551490

参考文献

[1] Zanetta, G., Rota, S., Chiari, S., Bonazzi, C., Bratina, G. and Mangioni, C. (2001) Behavior of Borderline Tumors with Particular Interest to Persistence, Recurrence, and Progression to Invasive Carcinoma: A Prospective Study. Journal of Clinical Oncology, 19, 2658-2664. [Google Scholar] [CrossRef] [PubMed]
[2] Hart, W.R. (2005) Borderline Epithelial Tumors of the Ovary. Modern Pathology, 18, S33-S50. [Google Scholar] [CrossRef] 
[3] Wang, D., Jia, S., Jia, C., Cao, D., Yang, J., Yang, J., et al. (2022) Oncological and Reproductive Outcomes after Fertility-Sparing Surgery in Patients with Seromucinous Borderline Ovarian Tumor: Results of a Large Retrospective Study. Gynecologic Oncology, 165, 446-452. [Google Scholar] [CrossRef] [PubMed]
[4] Vasconcelos, I. and de Sousa Mendes, M. (2015) Conservative Surgery in Ovarian Borderline Tumours: A Meta-Analysis with Emphasis on Recurrence Risk. European Journal of Cancer, 51, 620-631. [Google Scholar] [CrossRef] [PubMed]
[5] Johansen, G., Dahm-Kähler, P., Staf, C., Flöter Rådestad, A. and Rodriguez-Wallberg, K.A. (2021) Reproductive and Obstetrical Outcomes with the Overall Survival of Fertile-Age Women Treated with Fertility-Sparing Surgery for Borderline Ovarian Tumors in Sweden: A Prospective Nationwide Population-Based Study. Fertility and Sterility, 115, 157-163. [Google Scholar] [CrossRef] [PubMed]
[6] Morice, P., Scambia, G., Abu-Rustum, N.R., Acien, M., Arena, A., Brucker, S., et al. (2024) Fertility-sparing Treatment and Follow-Up in Patients with Cervical Cancer, Ovarian Cancer, and Borderline Ovarian Tumours: Guidelines from ESGO, ESHRE, and Esge. The Lancet Oncology, 25, e602-e610. [Google Scholar] [CrossRef] [PubMed]
[7] Colombo, N., Sessa, C., Du Bois, A., et al. (2019) ESMO-ESGO Consensus Conference Recommendations on Ovarian Cancer: Pathology and Molecular Biology, Early and Advanced Stages, Borderline Tumours and Recurrent Disease. Annals of Oncology, 30, 672-705.
[8] Baandrup, L., Faber, M.T., Aalborg, G.L. and Kjaer, S.K. (2020) Borderline Ovarian Tumors in Denmark 1997‐2018: Time Trends in Incidence by Histology, Age and Educational Level. Acta Obstetricia et Gynecologica Scandinavica, 100, 436-443. [Google Scholar] [CrossRef] [PubMed]
[9] Hauptmann, S., Friedrich, K., Redline, R. and Avril, S. (2016) Ovarian Borderline Tumors in the 2014 WHO Classification: Evolving Concepts and Diagnostic Criteria. Virchows Archiv, 470, 125-142. [Google Scholar] [CrossRef] [PubMed]
[10] Malpica, A. and Longacre, T.A. (2018) Prognostic Indicators in Ovarian Serous Borderline Tumours. Pathology, 50, 205-213. [Google Scholar] [CrossRef] [PubMed]
[11] Burks, R.T., Sherman, M.E. and Kurman, R.J. (1996) Micropapillary Serous Carcinoma of the Ovary. A Distinctive Low-Grade Carcinoma Related to Serous Borderline Tumors. The American Journal of Surgical Pathology, 20, 1319-1330. [Google Scholar] [CrossRef] [PubMed]
[12] Seidman, J.D. and Kurman, R.J. (1996) Subclassification of Serous Borderline Tumors of the Ovary into Benign Malignant Types. A Clinicopathologic Study of 65 Advanced Stage Cases. The American Journal of Surgical Pathology, 20, 1331-1345. [Google Scholar] [CrossRef] [PubMed]
[13] Shih, I. and Kurman, R.J. (2004) Ovarian Tumorigenesis: A Proposed Model Based on Morphological and Molecular genetic Analysis. The American Journal of Pathology, 164, 1511-1518. [Google Scholar] [CrossRef] [PubMed]
[14] Kurman, R.J. and Shih, I. (2016) The Dualistic Model of Ovarian Carcinogenesis. The American Journal of Pathology, 186, 733-747. [Google Scholar] [CrossRef] [PubMed]
[15] Kurman, R.J. (2013) Origin and Molecular Pathogenesis of Ovarian High-Grade Serous Carcinoma. Annals of Oncology, 24, x16-x21. [Google Scholar] [CrossRef] [PubMed]
[16] Sheu, J.J., Guan, B., Tsai, F., Hsiao, E.Y., Chen, C., Seruca, R., et al. (2012) Mutant BRAF Induces DNA Strand Breaks, Activates DNA Damage Response Pathway, and Up-Regulates Glucose Transporter-1 in Nontransformed Epithelial Cells. The American Journal of Pathology, 180, 1179-1188. [Google Scholar] [CrossRef] [PubMed]
[17] Ho, C., Kurman, R.J., Dehari, R., Wang, T. and Shih, I. (2004) Mutations of BRAF and KRAS Precede the Development of Ovarian Serous Borderline Tumors. Cancer Research, 64, 6915-6918. [Google Scholar] [CrossRef] [PubMed]
[18] Bell, D.A. (2005) Origins and Molecular Pathology of Ovarian Cancer. Modern Pathology, 18, S19-S32. [Google Scholar] [CrossRef] 
[19] Yoon, J., Dammann, R. and Pfeifer, G.P. (2001) Hypermethylation of the CPG Island of Therassf1a Gene in Ovarian and Renal Cell Carcinomas. International Journal of Cancer, 94, 212-217. [Google Scholar] [CrossRef] [PubMed]
[20] Cheng, E.J., Kurman, R.J., Wang, M., Oldt, R., Wang, B.G., Berman, D.M., et al. (2004) Molecular Genetic Analysis of Ovarian Serous Cystadenomas. Laboratory Investigation, 84, 778-784. [Google Scholar] [CrossRef] [PubMed]
[21] Malpica, A. and Wong, K. (2016) The Molecular Pathology of Ovarian Serous Borderline Tumors. Annals of Oncology, 27, i16-i19. [Google Scholar] [CrossRef] [PubMed]
[22] Sieben, N.L., Macropoulos, P., Roemen, G.M., Kolkman‐Uljee, S.M., Jan Fleuren, G., Houmadi, R., et al. (2004) In Ovarian Neoplasms, BRAF, but Not KRAS, Mutations Are Restricted to Low‐Grade Serous Tumours. The Journal of Pathology, 202, 336-340. [Google Scholar] [CrossRef] [PubMed]
[23] Tsang, Y.T., Deavers, M.T., Sun, C.C., Kwan, S., Kuo, E., Malpica, A., et al. (2013) KRAS (but Not BRAF) Mutations in Ovarian Serous Borderline Tumour Are Associated with Recurrent Low‐grade Serous Carcinoma. The Journal of Pathology, 231, 449-456. [Google Scholar] [CrossRef] [PubMed]
[24] McHenry, A., Rottmann, D.A., Buza, N. and Hui, P. (2023) KRAS Mutation in Primary Ovarian Serous Borderline Tumors Correlates with Tumor Recurrence. Virchows Archiv, 483, 71-79. [Google Scholar] [CrossRef] [PubMed]
[25] Zeppernick, F., Ardighieri, L., Hannibal, C.G., Vang, R., Junge, J., Kjaer, S.K., et al. (2014) BRAF Mutation Is Associated with a Specific Cell Type with Features Suggestive of Senescence in Ovarian Serous Borderline (Atypical Proliferative) Tumors. American Journal of Surgical Pathology, 38, 1603-1611. [Google Scholar] [CrossRef] [PubMed]
[26] Shih, I., Chen, L., Wang, C.C., Gu, J., Davidson, B., Cope, L., et al. (2010) Distinct DNA Methylation Profiles in Ovarian Serous Neoplasms and Their Implications in Ovarian Carcinogenesis. American Journal of Obstetrics and Gynecology, 203, 584.e1-584.e22. [Google Scholar] [CrossRef] [PubMed]
[27] Rathi, A., Virmani, A.K., Schorge, J.O., et al. (2002) Methylation Profiles of Sporadic Ovarian Tumors and Nonmalignant Ovaries from High-Risk Women. Clinical Cancer Research, 8, 3324-3331.
[28] Choi, Y., Kang, S.Y., Choi, J.S., Shin, Y.K., Kim, S.H., Lee, S., et al. (2005) Aberrant Hypermethylation of RASSF1A Promoter in Ovarian Borderline Tumors and Carcinomas. Virchows Archiv, 448, 331-336. [Google Scholar] [CrossRef] [PubMed]
[29] Farley, J., Brady, W.E., Vathipadiekal, V., Lankes, H.A., Coleman, R., Morgan, M.A., et al. (2013) Selumetinib in Women with Recurrent Low-Grade Serous Carcinoma of the Ovary or Peritoneum: An Open-Label, Single-Arm, Phase 2 Study. The Lancet Oncology, 14, 134-140. [Google Scholar] [CrossRef] [PubMed]
[30] Grisham, R.N., Vergote, I., Banerjee, S., Drill, E., Kalbacher, E., Mirza, M.R., et al. (2023) Molecular Results and Potential Biomarkers Identified from the Phase 3 Milo/engot-Ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer. Clinical Cancer Research, 29, 4068-4075. [Google Scholar] [CrossRef] [PubMed]
[31] Grisham, R.N. (2020) MILO/ENGOT-ov11: Phase-3 Study of Binimetinib versus Physician’s Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum. Gynecologic Oncology, 159, 22. [Google Scholar] [CrossRef] 
[32] Shetty, M.G., Pai, P., Deaver, R.E., Satyamoorthy, K. and Babitha, K.S. (2021) Histone Deacetylase 2 Selective Inhibitors: A Versatile Therapeutic Strategy as Next Generation Drug Target in Cancer Therapy. Pharmacological Research, 170, Article ID: 105695. [Google Scholar] [CrossRef] [PubMed]
[33] Saleh, M.H., Wang, L. and Goldberg, M.S. (2015) Improving Cancer Immunotherapy with DNA Methyltransferase Inhibitors. Cancer Immunology, Immunotherapy, 65, 787-796. [Google Scholar] [CrossRef] [PubMed]
[34] Tempfer, C., Polterauer, S., Bentz, E., Reinthaller, A. and Hefler, L. (2007) Accuracy of Intraoperative Frozen Section Analysis in Borderline Tumors of the Ovary: A Retrospective Analysis of 96 Cases and Review of the Literature. Gynecologic Oncology, 107, 248-252. [Google Scholar] [CrossRef] [PubMed]

为你推荐